Incyte
Bookmark
ShareCopied to clipboardIncyte is a company. It is a public company in Wilmington, the United States. It was founded in 1991 and its current CEO is Herve Hoppenot. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Wilmington
- country: United States
- employees: 2,617 people
- revenues: 4.2B $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 1991
- CEO: Herve Hoppenot
- CEO approval: 72 %
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about Incyte:
Dataset of stocks from Incyte:
Incyte is one of the companies in the United States, companies in Biotechnology, companies in Health Care, companies in Wilmington and 3,456,808 companies in our database.
Talking Points
- Biopharmaceutical Company | Solutions for Unmet Medical Needs |Incyte.com
- Incyte is a global biopharmaceutical company focused on finding innovative solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines..
- Incyte’s official Twitter. Ready to Solve On. See our Community Guidelines: https://t.co/DD2VZaemus
- Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. We are committed to the relentless pursuit of science that can improve the lives of patients. Our unique expertise in medicinal chemistry and biology has enabled us to create ...
- Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.